STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

GHRP-6

Also known as

Growth hormone releasing peptide-6 · Growth hormone-releasing hexapeptide · GH-releasing peptide-6 · GHRP 6 · GHRP6 · His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 · HwAWfK-NH2 · SK&F 110679 · SKF-110679 · SKF 110679 · Hexapeptide-2 · U 75799E

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic SubQ Growth hormone axis

Systemic — ghrelin-receptor peptide discussed for GH pulses, appetite, recovery and body composition; not local joint or muscle targeting.

What people say GHRP-6 is a synthetic ghrelin-receptor peptide discussed for GH pulses and, especially, appetite during bulking. It is distinct from HGH and the longer-acting oral secretagogue MK-677. Doses people talk about
Community charts100–300 mcg subcutaneously per administration; one to three daily administrations discussed

A separate chart describes 100 mcg once daily, often at bedtime, for about one week before discussing AM/midday additions. These are reported templates, not a validated progression.

Bodyweight-ceiling loreAbout 1 mcg/kg per reported pulse

Community SC discussion quotes roughly 80 mcg at 80 kg or 100 mcg at 100 kg, and about 100 mcg per pulse with a GHRH partner. This is not a measured SC ceiling or established safety threshold.

Single-dose IV research100, 200 or 400 mcg/kg intravenously once

Cabrales studied nine healthy men at research exposures far above community SC charts. Parent-peptide distribution and terminal elimination were measured separately; these are not interchangeable routes or physique regimens.

Reported amounts, not recommendations. Routes, populations and exposure patterns are not interchangeable; hunger does not measure the GH response.

Half-life & effect duration

Half-life in the body
  • IV · terminal clearanceAbout 2.5 hours
Felt duration people report
  • Hunger onsetAbout 20–30 minutes in one log
  • Hunger duration · that logAbout 90 minutes
  • Other community duration reportsAbout 30–60+ minutes
  • Later in the courseFatigue and changing appetite
Timing context & sources
How it may feel Accounts describe intense hunger, warmth, flushing, a head rush or fatigue, with sleep and water/fullness changes in some logs. Threads also discuss a missing hunger wave; appetite is not proof of a useful GH or IGF-1 change.
Cycles people discuss Charts describe 4–6-week probes, 8–12- or 12–16-week blocks and 4–8 weeks off. Daily use and 5-on/2-off weeks both appear; neither is a validated body-composition cycle. Timing Morning fasted, optional afternoon and bedtime use appear in chart discussion. Some place meals around the hunger wave; others find that disruptive. The quoted 2–3 hours after food and 20–30-minute wait are reported practices, not a universal rule. Stacks Classic dual pulse: GHRP-6 + Mod GRF 1-29 (CJC-1295 no DAC) — ‘gold standard’ forum stack; often ~100 mcg each, same syringe, 2–3×/day empty stomach. Access talk 2026 shelves: RUO vials and leftover “CJC/GHRP-6” blends. Category 3 / 503B-2 is not a clinic green light. Labs people mention IGF-1 is the usual “did the axis move” check after a few weeks of multi-daily pulses + a GHRH partner. Solo GHRP-6 may barely move a morning trough. Watch for Intense hunger: Defining downside for non-bulk goals; can wreck fat-loss phases; onset often ~15–30 min post-injection and can last ~30–60+ min.
Related
GHRP-2IpamorelinHexarelinCJC-1295Sermorelin

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 2.5 hours in a small intravenous study in healthy men.

The earlier distribution phase was about eight minutes. Neither number directly establishes subcutaneous timing or the duration of hunger.

Cabrales reports elimination 2.5 ± 1.1 h and distribution 7.6 ± 1.9 min, with late concentration spikes in four of nine subjects. The IV study exposures differ substantially from community SC discussion. Detection around 12 hours is not guaranteed clearance or safety.

Felt duration people report

One dated log describes hunger starting after 20–30 minutes and lasting about 90 minutes.

The same person later reports fatigue and changes in appetite across the course. Other compounds and changing use make attribution uncertain.

This is a 2007 account, not current prevalence or an isolated GHRP-6 trial. EQ/testosterone are acknowledged by the poster. Onset, wave duration and days of use remain separate; the post's dose changes and causal guesses are not recommendations.

  • Just Started GHRP-6 — dated T Nation log (opens in a new tab)sota123, post 1 (22 October 2007): onset and 90-minute appetite duration; post 6 (23 October): SC route; post 9 (29 October): changed appetite and low energy.First-person dated log reviewed. Concurrent EQ/testosterone and later use changes; old individual experience cannot establish prevalence or a safe routine.

What people say 15

  • Saturation lore: Community and secondary writeups cite ~1 mcg/kg per pulse (~80 mcg for an ~80 kg adult; ~100 mcg for a ~100 kg adult) as near-ceiling for GH per bolus — more mcg mainly buys sides (hunger, cortisol/prolactin talk), not proportional GH. forum
  • Appetite as intended lever: Intense, often rapid hunger is the defining practical ‘benefit’ in bulk logs — used to force surplus calories that training alone did not deliver. forum
  • Hard-gainer bulk stories: Scale weight, fullness, and lean-looking mass gains in surplus; hunger-driven intake makes pure peptide attribution weak. anecdote
  • Recovery stories: Easier day-to-day bounce-back and less DOMS over multi-week runs — almost always confounded by surplus eating, sleep, and GHRH partners. forum
  • Sleep adjacency: Bedtime empty-stomach pulse is discussed for deeper sleep / dream intensity via amplifying nocturnal GH — less central than Ipamorelin sleep lore, but still present; many charts call the pre-bed shot the priority single pulse. forum
  • Stack credit: Many ‘GHRP-6 results’ are pinned to GHRP-6 + Mod GRF 1-29 / CJC no-DAC dual-pathway pulses, not mono-therapy. forum
  • vs GHRP-2: Hungrier and often more cortisol/prolactin talk; GHRP-2 cast as stronger peak GH with milder ravenous effect and somewhat cleaner secondary-hormone chatter. forum
  • vs Ipamorelin: Kept when appetite stimulation is wanted on purpose; dropped when cuts, sleep-only, or ‘clean GH’ goals dominate (Ipamorelin = negligible cortisol/prolactin/hunger lore). forum
  • vs Hexarelin: Hexarelin lore emphasizes even stronger GH and more desensitization/tachyphylaxis concern; GHRP-6 sits in the classic bulk-hunger niche with intermediate attenuation talk. forum
  • vs MK-677: Discrete injectable pulses + acute hunger waves vs long oral ghrelin-mimetic elevation with different water/glucose discussion — different tools, sometimes compared as alternates. forum
  • IGF-1 proxy talk: Some users recheck morning IGF-1 after multi-week multi-daily runs as a crude ‘axis engaged’ check; not a validated physique surrogate. forum
  • Acute dose-dependent GH pulse: Human and earlier experimental work show clear GH release; peak GH often described ~15–30 min post-dose (SC talk), with the functional pulse lasting roughly ~60–90 min rather than all day. trial
  • GHRH combo synergy (trial orientation): Popovic et al. 1995 (IV challenges) — example mean GH AUC figures in normal subjects: GHRH ~483.7, GHRP-6 ~1434.8, GHRH+GHRP-6 ~3771.5 μg·L⁻¹·120 min, with combo significantly above the arithmetic sum; used as the endocrine rationale for dual-pathway stacks, not a personal outcome guarantee. trial
  • Secondary synergy quotes: Protocol blogs often compress class synergy to ~2–3× GHRP-alone style figures (including ~2.6× GHRP-6-alone claims from secondary writeups of related GHRH co-challenge data) — orientation only; study doses/routes differ from gym SC practice. trial
  • Preclinical cytoprotection: Cuban and other programs report cardioprotective / cytoprotective signals (e.g., infarct size reduction in large-animal models, doxorubicin myocardial damage models) via GHS-R and/or CD36-adjacent prosurvival pathways — not the reason gym forums dose it. animal

Doses people talk about 21

  • Per-injection band: ~100–300 mcg subcutaneous per dose is the constant beginner/intermediate figure across protocol sheets and forums. forum
  • Saturation / starting anchor: ~1 mcg/kg per pulse is the most-cited near-ceiling community dose (≈80 mcg at 80 kg; ≈100 mcg at 100 kg); many stay at ~100 mcg/pulse when stacked with a GHRH analog. forum
  • One-dose chart reports: Some charts describe 100 mcg subcutaneously once daily, often bedtime only, for ~1 week to gauge hunger tolerance, with later AM/midday additions also discussed. This is reported self-experimentation, not a validated starting point or escalation sequence. forum
  • Standard community template: ~100 mcg per injection, 2–3× daily (AM fasted, post-training or midday, bedtime), empty stomach. forum
  • Intermediate variants: ~100–200 mcg, 2–3× daily; some self-report medians land in higher buckets but secondary writeups still warn diminishing GH returns past saturation. forum
  • Aggressive / advanced sheets: ~100–150 mcg (sometimes up to ~200–300 mcg) three times daily, often already paired with a GHRH analog, for 12–16 week blocks. forum
  • Titration ladders (vendor/protocol charts): Some writeups escalate Weeks 1–2 at 100 mcg 3×/day → Weeks 3–4 at 200 mcg → Weeks 5–12 at 300 mcg — progressive charts are community constructs, not trial standards. forum
  • Frequency spacing: Doses separated by ~3–4+ hours so each pulse is discrete; multi-daily logic follows short pulse window, not depot. forum
  • With GHRH partner (classic dual pulse): ~100 mcg GHRP-6 + ~100 mcg Mod GRF 1-29 / CJC no-DAC per pulse, same timing, often same syringe — do not double GHRP-6 just because it is stacked. forum
  • Aggressive stack variants: ~100–150 mcg GHRP-6 + ~100–200 mcg Mod GRF per pulse, 2–3×/day, for 12–16 week blocks appears in advanced sheets. forum
  • Sermorelin partner doses: Same dual-pulse idea with sermorelin as the GHRH path when CJC/Mod GRF is not used — partner mcg still chart-dependent. forum
  • Empty stomach rule: Common guidance is ≥~2–3 hours after food (especially carbs/fats; elevated glucose/insulin said to blunt GH) and wait ~20–30+ minutes (some guides ~30–60) before eating. forum
  • Hunger-as-timer practice: Many intentionally dose pre-meal so the ghrelin-like wave drives the next feed rather than fighting it — especially useful on bulk. forum
  • Upper-end caution: ~200–300+ mcg/pulse raises hunger intensity, water, and cortisol/prolactin spillover talk with diminishing GH returns past ~1 mcg/kg saturation lore. forum
  • Cut/bulk disagreement: Some charts place ~100 mcg per pulse beside GH-with-less-hunger claims and 200–300 mcg beside “ravenous” reports. These are community amount-and-response attributions, not a reliable way to predict an individual hunger wave or a direction to stay at a particular dose. forum
  • Pre-meal vs pre-bed: Pre-meal uses the hunger; pre-bed hopes you sleep through it — mixed success in 2025–26 logs. forum
  • Daily totals discussed: Roughly ~200–900 mcg/day appears in multi-dose summaries, alongside the separate 100 mcg once-daily chart. Charts describe 1–3 shots at 100–300 mcg each; the quoted 200–900 range is not exhaustive. The 3×100 mcg (~300 mcg/day) and 3×100–200 mcg patterns remain common templates. Older clinic-adjacent notes sometimes cite class totals ~100–500 mcg/day injectable GHRP with higher stacked ceilings next to sermorelin — not standardized gym RCTs. forum
  • Purity / fill flag: Labeled mcg may not match delivered peptide without third-party testing; research-chem underdosing and mislabeling are structural risks. forum
  • Clinical IV scale (not gym protocol): Cabrales et al. 2013 healthy-volunteer PK used single IV boluses of 100, 200, or 400 μg/kg — orders of magnitude above community mcg SC practice; used for PK/safety characterization. trial
  • Historical oral / IN (not practical modern route): Oral GHRP-6 showed GH activity in short children (Bellone 1995; peak GH example ~18.8 mcg/L at 60 min in that pediatric cohort) but oral bioavailability is summarized as very low (~0.3% in secondary GHS reviews; Wikipedia-class summaries often list oral BA <1%); dog IN bioavailability ~34–45% was research-era, not standard community practice. trial
  • Framing: Community- and research-discussed ranges only — not advice, not prescriptions, not safety-validated physique protocols. forum

How it may feel 10

  • Minutes post-shot: Intense hunger often within ~15–30 min for sensitive users (some say ‘within minutes’); brief flush, head-rush, warmth, tingling, or site sting also common first exposures. forum
  • First hours: Hunger wave frequently lasts ~30–60+ min; many plan a meal in the post-dose window rather than fighting it. Acute GH elevation window is discussed as largely over within a few hours — not all-day like MK-677. forum
  • Days 1–7: Appetite spikes on every pulse become the dominant experience; water/fullness, vivid dreams on bedtime doses, and early recovery notes appear in some logs. forum
  • Weeks 1–2: Surplus eating gets easier if bulk is the goal; cutters often reassess quickly as hunger fights the diet. Sleep depth sometimes improves with night dosing. forum
  • Weeks 3–4: Checkpoint for water (rings/face), mood, sleep quality, libido/lethargy (prolactin/cortisol talk), fasting-glucose curiosity, and whether dose is above saturation without extra GH benefit. forum
  • Weeks 6–8: Body-comp and recovery claims become more visible in surplus + training logs; still confounded by calories and stacks. anecdote
  • Weeks 10–16: Cumulative size/recovery stories peak in bulk blocks; some report GH-response plateau lore and plan an off block. Appetite stimulation often stays strong (does not reliably ‘fade’ the way some expect). forum
  • Beyond ~16 weeks continuous: Community cycling guides flag diminishing GH-response risk from prolonged continuous GHS use; off-block or rotate talk increases. forum
  • If there is no hunger: 2026 threads treat a silent pin as timing, fill, or a mislabeled vial before “GHRP-6 doesn’t work on me.” Hunger still isn’t proof of a GH pulse. forum
  • Week 1 quit on a cut: Appetite wrecking the deficit in days is the usual GHRP-6 → ipamorelin or GHRP-2 swap, not a 4-week test. forum

Around the dose 6

  • Clock reports: Community charts describe AM fasted, optional afternoon and bedtime empty-stomach pulses, commonly totaling 2–3 per day. Some place use near an intended meal to use the appetite wave; others find the hunger disruptive. These are reported routines, not a timing instruction. forum
  • Hunger-as-timer: Wave often ~15–30 min post-shot. 2026 bulk logs treat that as the meal alarm; cut logs treat it as a reason to pick ipamorelin. forum
  • Food-timing lore: Protocol discussions describe ~2–3 hours after food and a wait of ~20–30 minutes before eating, with bulking accounts often placing a meal afterward. These are community practices, not clearance-derived requirements or an instruction to eat after a particular interval. forum
  • Training: Not a pre-workout pump. Hunger 20 min before a session is a common “why did I pin this now” post. forum
  • Afterward: Bulking accounts discuss a planned calorie surplus and meals around the appetite wave, while cutting accounts describe fighting that hunger as disruptive to a deficit. This contrast is reported experience, not a direction to eat more or use or avoid a peptide. forum
  • Partner: CJC no-DAC / Mod GRF same syringe is still the dual-pulse default; two GHRPs together is still called redundant. forum

Cycles people discuss 12

  • Common bulk/recovery block: 8–12 weeks on is the most repeated community template. forum
  • Longer bulk template: 12–16 weeks on appears when paired with Mod GRF and a planned surplus. forum
  • Short probe: 4–6 weeks to test hunger tolerance vs switching to Ipamorelin or GHRP-2. forum
  • Time off: Often ~4–8 weeks off after multi-month runs — rationales include GHS-receptor attenuation folklore, cost, IGF-1 ‘reset’ talk, and checking whether appetite/recovery hold. forum
  • On/off examples discussed: 8–16 weeks on / 4–8 weeks off is a common chart pattern; some sources also cite ~8 on / 8 off style symmetry — not trial-standardized. forum
  • 5-on / 2-off weekly pattern: Older minority GHRP pattern still appears; rationale is consecutive-day response attenuation talk from broader secretagogue literature rather than a GHRP-6-specific large RCT. forum
  • Daily multi-dose modern logs: Many current users run every day at 2–3× without weekend off; comparative superiority is anecdotal. forum
  • No loading phase: Protocols describe flat mcg from day one (or slow titration for hunger/sides), not a load/maintain split. forum
  • Continuous multi-daily use: Open-ended year-round use is debated; long-term safety data in healthy self-experimenters are thin; guides often flag continuous use past ~16 weeks for plateau/desensitization concern. forum
  • Desensitization management: Pulsatile 2–3×/day (not continuous infusion) and cycling off are the main community mitigations; Hexarelin is usually cast as worse for tachyphylaxis than GHRP-6, with Ipamorelin as least. forum
  • Rotation tactic: Some rotate to Ipamorelin or GHRP-2 during off blocks rather than full secretagogue abstinence. forum
  • Re-runs: Restart around bulk blocks when appetite drive is wanted again, or when recovery feels stalled after time off. forum

Timing 10

  • Pulse duration talk: Elevated GH often framed as lasting on the order of ~1–3 hours before returning toward baseline depending on source — still discrete pulses, not MK-677-style all-day elevation. forum
  • Why 2–3×/day is discussed: Community charts use short-pulse logic for separate AM/mid/PM shots hours apart, with ≥~3–4 hours commonly quoted. That is reported scheduling rationale, not validation of a frequency or spacing rule from the human IV half-life. forum
  • IGF-1 lag: Acute GH spike vs slower composition / recovery claims over weeks of repeated pulses. forum
  • Food / glucose blunting: Recent meals and high glucose/insulin (and fat/carb-heavy windows in protocol lore) are widely said to blunt GH response — empty-stomach dosing dominates protocol culture. forum
  • Vs MK-677: Discrete injectable pulses + acute hunger waves vs long oral ghrelin-mimetic elevation with different water/glucose discussion. forum
  • Vs CJC with DAC: GHRP-6 stays short-acting even if someone pairs it with long-acting GHRH — pulse logic for GHRP-6 does not become weekly. forum
  • Receptor attenuation lore: Chronic high-dose / prolonged continuous GHS use can blunt GH response over time in the broader literature/community (Hexarelin >> GHRP-6/GHRP-2 > Ipamorelin lore); drives off-blocks more than a GHRP-6-specific long RCT. forum
  • Human IV PK (Cabrales 2013): Nine healthy men; single IV boluses 100/200/400 μg/kg; bi-exponential disposition; average distribution t½ ~7.6 ± 1.9 min and elimination t½ ~2.5 ± 1.1 h across dose levels; LLOQ still reached at 12 h post-dose in that assay context. trial
  • Peak GH timing: ~15–30 min post-dose is the usual SC/community and clinical description; multi-daily pulses, not weekly depot. trial
  • GHRH co-admin synergy: Distinct receptor pathways (GHS-R1a vs GHRHR) amplify each other in intact humans; disconnection models blunt GHRP-6 and remove synergy — supports dual-pathway stacks mechanistically. trial

More on what it is 8

  • Why people use it: Strong endogenous GH pulses plus the hungriest classic GHRP — bulk and hard-gainer threads treat the appetite spike as a feature; cutters often treat it as a liability and switch to Ipamorelin or GHRP-2. forum
  • Signature vs peers: Strongest hunger among common GHRPs; more cortisol/prolactin spillover talk than Ipamorelin at higher doses; often cast as slightly less GH-potent than GHRP-2 head-to-head in forum tables, with Hexarelin cast as even more aggressive. forum
  • What it is: Synthetic hexapeptide (~872.44 Da free base; sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 / HwAWfK-NH2) that agonizes GHS-R1a (ghrelin receptor). First-in-class GHRP from Bowers / Momany enkephalin-analog work in the mid-1980s (developmental code SK&F 110679); research tool and gray-market peptide, not an approved physique drug. trial
  • Mechanism talk: Direct somatotroph GH release via GHS-R1a (PLC/IP3/Ca2+ path) plus hypothalamic actions; also engages central hunger circuits (NPY/AgRP / ghrelin-pathway lore). Full GH response needs endogenous GHRH tone — basis for stacking with GHRH analogs. trial
  • Evidence honesty: Human IV PK (Cabrales 2013), acute GH-release studies, historical oral activity in short children (Bellone 1995), and substantial preclinical cytoprotection literature exist; large RCTs for multi-daily body-comp or recovery protocols do not. trial
  • Sport status: Explicitly listed under WADA S2 GH-releasing peptides (GHRPs) — prohibited at all times (in- and out-of-competition) for tested athletes. trial
  • Not: Not recombinant HGH, not a steroid/SARM, not MK-677 (oral long secretagogue), not the ‘cleanest’ selective GHRP (that lore goes to Ipamorelin), not FDA-approved for muscle, fat loss, recovery, or anti-aging. trial
  • Synergy framing: Human work (e.g., Popovic et al. 1995) shows striking GHRP-6 + GHRH synergy on GH release — combo AUC far above either alone and above arithmetic sum in intact subjects; hypothalamo-pituitary disconnection blunts GHRP-6 and kills synergy, supporting a hypothalamic contribution. trial

Stacks 10

  • Classic dual pulse: GHRP-6 + Mod GRF 1-29 (CJC-1295 no DAC) — ‘gold standard’ forum stack; often ~100 mcg each, same syringe, 2–3×/day empty stomach. forum
  • CJC with DAC + GHRP-6: Still sold and discussed for convenience / IGF-1 elevation lore; pulse purists often prefer no-DAC to keep short coordinated pulses. forum
  • Sermorelin + GHRP-6: Another GHRH partner in clinic/forum talk when CJC/Mod GRF is not used. forum
  • Premixed blend vials: Research-chem market sells fixed-ratio Mod GRF/GHRP-6 or CJC/GHRP-6 combos — composition varies by vendor; always read label math. forum
  • Bulk lifestyle stack: High-calorie surplus ± other agents; hunger from GHRP-6 is often the real surplus lever more than the peptide alone. forum
  • MK-677 combo or alternate: Oral continuous secretagogue compared or occasionally stacked (e.g., MK 20–25 mg PM talk + multi-daily GHRP pulses); doubles hunger/water/glucose concern — often debated rather than recommended. forum
  • Ipamorelin co-use or switch: Some sheets briefly pair GHRPs or rotate; more often users switch to Ipamorelin when hunger/spillover wins. Two GHS-R1a agonists together are generally framed as non-synergistic vs one GHRP + one GHRH. forum
  • Historical two-GHRP mixes: Older GHRP-2 + GHRP-6 blend talk exists; modern logs usually pick one GHRP and one GHRH instead. forum
  • Recovery adjacency: BPC-157 ± TB-500 (‘Wolverine’-style) layered for soft-tissue goals alongside GH-axis work — separate mechanisms, highly confounded. forum
  • vs running alone: Many never run GHRP-6 solo after dual-pulse marketing; mono use still appears when cost or simplicity rules. forum

Access talk 5

  • 2026 shelves: RUO vials and leftover “CJC/GHRP-6” blends. Category 3 / 503B-2 is not a clinic green light. forum
  • Not on the July 2026 PCAC seven. trial
  • 503A: GHRP-6 is Category 3 on FDA’s May 14, 2026 nominated-bulks table — nominated without adequate support. trial
  • 503B Category 2: FDA flags immunogenicity (aggregation/impurities) and limited safety data that includes cortisol effects and increased blood glucose from decreased insulin sensitivity. trial
  • WADA S2: Named GHRP-6 — prohibited at all times for tested athletes. trial

Labs people mention 4

  • IGF-1 is the usual “did the axis move” check after a few weeks of multi-daily pulses + a GHRH partner. Solo GHRP-6 may barely move a morning trough. forum
  • Glucose: FDA’s 503B note already flags insulin-sensitivity / blood-glucose concern — forums watch fasting glucose on longer bulk runs. trialforum
  • Prolactin / cortisol: quieter than hexarelin talk, louder than ipamorelin; checked when libido/mood or high-mcg 3×/day is in the log. forum
  • If IGF-1 is flat: food near the pin, no GHRH partner, or a weak vial — not an automatic jump to 300 mcg. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 19

  • Intense hunger: Defining downside for non-bulk goals; can wreck fat-loss phases; onset often ~15–30 min post-injection and can last ~30–60+ min. forum
  • Cortisol / ACTH spillover: Dose-dependent; more spillover talk than Ipamorelin, often described as worse than GHRP-2 in forum tables; elevations generally framed as transient at discussion doses but more notable above ~saturation (~1 mcg/kg). forum
  • Prolactin spillover: Mild at ~100 mcg talk; more discussion of mood, libido, and rare gynecomastia concern when doses push higher or sensitivity is high. forum
  • Water retention: Face puff, tight rings, scale jumps from fluid — especially early and on multi-daily higher-end dosing. forum
  • Injection site: Redness, sting, itch, irritation with poor technique or same-site reuse; rotate sites (lipodystrophy lore). forum
  • Flush / head rush: Brief warmth, flushing, tingling, or light head pressure on first doses is common. forum
  • Fatigue / lethargy / drowsy: Post-pulse tiredness in some logs, especially pre-bed timing; stacks, training, and sleep confound. forum
  • Glucose / insulin talk: GH opposes insulin action; some monitor fasting glucose; diabetic/insulin-resistant contexts get extra caution in endocrine writeups. forum
  • Carpal-tunnel-like tingling: Hand/finger pins-and-needles framed as GH-related fluid pressure on aggressive multi-pulse runs. forum
  • Headache: Minority reports; causality soft amid training and sleep debt. forum
  • Desensitization / attenuated GH response: Prolonged continuous high-dose use may blunt response (less feared than Hexarelin; more than Ipamorelin in bro ranking); community cycles and pulse spacing are the main mitigations discussed. forum
  • Malignancy / growth-pathway caution: Elevated GH/IGF-1 raises theoretical oncologic concern in literature; GHS trial designs often exclude active cancer — general axis caution, not a GHRP-6-only risk table. forum
  • Source quality: Gray-market mislabeling, under-dosing, and contamination risk is structural. forum
  • Forum silence ≠ safety: Lack of dramatic community reports does not equal established long-horizon risk profile in healthy self-experimenters. forum
  • Ravenous hunger is the watch-for: 15–30 min post-pin, 30–60+ min window — feature on a bulk, disqualifier on a cut. forum
  • Water / carpal / glucose: Same GH-axis triad as other GHRPs when pulses stack. forum
  • Don’t read hunger as GH: The ghrelin-appetite arm can fire without proving a useful GH/IGF-1 change. forum
  • WADA / sport: Explicitly named under S2 GHRPs (GHRP-6) — prohibited at all times for tested athletes. trial
  • Not approved for body-comp uses: Not FDA-approved for muscle, fat loss, recovery, or anti-aging; human PK/safety scale-up and acute endocrine challenges ≠ long-term multi-daily wellness proof. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →